CureVac indicates immune response from COVID-19 vaccine candidate
German biotech firm CureVac N.V. yesterday announced interim data from its ongoing Phase 1 dose-escalation study evaluating its CVnCoV SARS-CoV-2 vaccine candidate for safety, reactogenicity and immunogenicity.
CureVac said it has early indications that CVnCoV generates a balanced immune response, similar to that of natural COVID-19 infection. The drug maker said its data supports the beginning of a Phase 2b/3 clinical trial before the end of 2020 for a 12 microgram dose of the candidate.
Related News Articles
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…